Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increased thrombotic vascular events after change of statin.

× No keyword cloud information.

26 in total

Review 1. Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements.

Authors: A Woodfield
Journal: Pharmacoeconomics Date: 2001 Impact factor: 4.981

Review 2. Isoprenoid metabolism and the pleiotropic effects of statins.

Authors: Ulrich Laufs; James K Liao
Journal: Curr Atheroscler Rep Date: 2003-09 Impact factor: 5.113

Review 3. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Authors: Lisa L Ioannides-Demos; Joseph E Ibrahim; John J McNeil
Journal: Pharmacoeconomics Date: 2002 Impact factor: 4.981

Review 4. Effects of reference pricing in pharmaceutical markets: a review.

Authors: Matteo Maria Galizzi; Simone Ghislandi; Marisa Miraldo
Journal: Pharmacoeconomics Date: 2011-01 Impact factor: 4.981

5. Reference drug programs: effectiveness and policy implications.

Authors: Sebastian Schneeweiss
Journal: Health Policy Date: 2006-06-13 Impact factor: 2.980

Review 6. Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data.

Authors: Anders G Olsson
Journal: Curr Atheroscler Rep Date: 2006-09 Impact factor: 5.113

7. Drug discontinuation effects are part of the pharmacology of a drug.

Authors: Marcus M Reidenberg
Journal: J Pharmacol Exp Ther Date: 2011-08-17 Impact factor: 4.030

8. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.

Authors: Philip S Wang; Amanda R Patrick; Colin Dormuth; Malcolm Maclure; Jerry Avorn; Claire F Canning; Sebastian Schneeweiss
Journal: J Ment Health Policy Econ Date: 2010-03

9. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.

Authors: Pearl D Gumbs; W M Monique Verschuren; Patrick C Souverein; Aukje K Mantel-Teeuwisse; G Ardine de Wit; Anthonius de Boer; Olaf H Klungel
Journal: Br J Clin Pharmacol Date: 2007-09-13 Impact factor: 4.335

10. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Authors: Aukje K Mantel-Teeuwisse; Olaf H Klungel; Toine C G Egberts; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Journal: Drug Saf Date: 2004 Impact factor: 5.606